Vimarsana
Biggest News Aggregation in the World

Wechsler Memory Scale News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Wechsler Memory Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Wechsler Memory Scale Today - Breaking & Trending Today

Poverty Tied to Poor Cognition in Patients With Epilepsy - Vimarsana News

Poverty Tied to Poor Cognition in Patients With Epilepsy

Mounting research links poverty and other elements of neighborhood deprivation to worse cognition in people with epilepsy.

Early Intervention With Nutrient Supplementation May Be Beneficial to Patients with Alzheimer Disease - Vimarsana News

Early Intervention With Nutrient Supplementation May Be Beneficial to Patients with Alzheimer Disease

Through previous literature, investigators found that intervention with nutritional supplements may help to improve cognitive performance and reduce the severity of memory impairment in adults with Alzheimer disease.

Patients With Bipolar Disorder May Have Unique Age-Related Cognitive Decline - Vimarsana News

Patients With Bipolar Disorder May Have Unique Age-Related Cognitive Decline

A cross-sectional study found evidence that cognitive domains are affected by aging differently among the bipolar disorder population.

#VisualAbstract: Lecanemab reduced cognitive and functional decline in early Alzheimer's disease compared to placebo - Vimarsana News

#VisualAbstract: Lecanemab reduced cognitive and functional decline in early Alzheimer's disease compared to placebo

1. Lecanemab was associated with reduced amyloid markers in early Alzheimer’s disease as compared to placebo. 2. Lecanemab also resulted in moderately less decline in cognitive and functional measures at 18-month follow-up as compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Rates of Alzheimer’s disease are increasing annually, introducing a considerable burden to

Lecanemab may slow cognitive decline in early Alzheimer's disease - Vimarsana News

Lecanemab may slow cognitive decline in early Alzheimer's disease

1. Lecanemab was associated with reduced amyloid markers in early Alzheimer’s disease as compared to placebo. 2. Lecanemab also resulted in moderately less decline in cognitive and functional measures at 18-month follow-up as compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Rates of Alzheimer’s disease are increasing annually, introducing a considerable burden to